Genmab A/S (GNMSF)
337.00
+9.30
(+2.84%)
USD |
OTCM |
Aug 25, 16:00
Genmab Enterprise Value : 23.89B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 23.89B |
| August 24, 2026 | 23.33B |
| August 21, 2026 | 23.89B |
| August 20, 2026 | 23.77B |
| August 19, 2026 | 22.87B |
| August 18, 2026 | 22.87B |
| August 17, 2026 | 22.87B |
| August 14, 2026 | 22.31B |
| August 13, 2026 | 22.31B |
| August 12, 2026 | 22.37B |
| August 11, 2026 | 22.37B |
| August 10, 2026 | 22.37B |
| August 07, 2026 | 22.37B |
| August 06, 2026 | 21.38B |
| August 05, 2026 | 21.08B |
| August 04, 2026 | 21.07B |
| August 03, 2026 | 20.61B |
| July 31, 2026 | 21.03B |
| July 30, 2026 | 21.03B |
| July 29, 2026 | 21.03B |
| July 28, 2026 | 21.03B |
| July 27, 2026 | 20.84B |
| July 24, 2026 | 20.16B |
| July 23, 2026 | 20.16B |
| July 22, 2026 | 20.16B |
| Date | Value |
|---|---|
| July 21, 2026 | 20.16B |
| July 20, 2026 | 20.16B |
| July 17, 2026 | 20.61B |
| July 16, 2026 | 20.84B |
| July 15, 2026 | 20.84B |
| July 14, 2026 | 20.84B |
| July 13, 2026 | 20.84B |
| July 10, 2026 | 20.24B |
| July 09, 2026 | 20.70B |
| July 08, 2026 | 21.01B |
| July 07, 2026 | 20.62B |
| July 06, 2026 | 20.62B |
| July 02, 2026 | 20.19B |
| July 01, 2026 | 20.19B |
| June 30, 2026 | 20.19B |
| June 29, 2026 | 19.91B |
| June 26, 2026 | 19.91B |
| June 25, 2026 | 19.91B |
| June 24, 2026 | 19.63B |
| June 23, 2026 | 19.63B |
| June 22, 2026 | 19.18B |
| June 18, 2026 | 19.13B |
| June 17, 2026 | 19.13B |
| June 16, 2026 | 19.11B |
| June 15, 2026 | 19.11B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascendis Pharma A/S | 16.20B |
| Zealand Pharma A/S | 1.468B |
| Bavarian Nordic A/S | 2.230B |
| Evaxion AS | 21.04M |
| ACADIA Pharmaceuticals, Inc. | 4.379B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 303.00M |
| Revenue (Quarterly) | 1.155B |
| Total Expenses (Quarterly) | 852.00M |
| EPS Diluted (Quarterly) | 4.91 |
| Gross Profit Margin (Quarterly) | 92.73% |
| Profit Margin (Quarterly) | 26.23% |
| Earnings Yield | 3.76% |
| Operating Earnings Yield | 6.21% |
| Normalized Earnings Yield | 4.582 |